检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:朱小生[1] 胡晓文[1] 操乐杰[1] 高圣堂[1] 徐飞[1] 夏淮玲[1]
机构地区:[1]安徽医科大学附属省立医院呼吸科,合肥230001
出 处:《临床肺科杂志》2009年第2期194-195,共2页Journal of Clinical Pulmonary Medicine
基 金:安徽省2008年科技计划项目资助(编号08020303088)
摘 要:目的探讨恩度联合化疗的疗效、毒副作用及生存率影响。方法采用标准肺癌化疗方案(GP/NP)联合恩度15mg/天,观察2个以上疗程治疗后疗效并随访。结果恩度联合化疗有效率(CR+PR)达46.2%,明显优于单纯化疗,而毒副作用轻微。结论恩度联合化疗能增加疗效,毒副作用可以耐受,值得临床推广。Objective To evaluate the efficacy , safety and survival rate of EndostarTM (YH-16) combined with chemotherapy for non-small cell lung cancer (NSCLC). Methods The patients were treated with more than 2 cycles of standard chemotherapy regimen (GP/NP) combined with YH-16 (15 mg/d). The efficacy was observed and the patients were follow-up visited. Results The response rate ( CR + PR) of the treatment group obviously surpassed the control group (48. 1% versus 14. 3 % , P 〈 0. 005 ), and the toxicity was little. Conclusion Significant efficacy and safety against NSCLC were observed in YH-16 in combination with chemotherapy compared with chemotherapy alone. It is worthy of extensive clinical application.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.229